[go: up one dir, main page]

WO2007112940A3 - Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same - Google Patents

Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same Download PDF

Info

Publication number
WO2007112940A3
WO2007112940A3 PCT/EP2007/002817 EP2007002817W WO2007112940A3 WO 2007112940 A3 WO2007112940 A3 WO 2007112940A3 EP 2007002817 W EP2007002817 W EP 2007002817W WO 2007112940 A3 WO2007112940 A3 WO 2007112940A3
Authority
WO
WIPO (PCT)
Prior art keywords
albumin
entities
life
amino acid
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/002817
Other languages
French (fr)
Other versions
WO2007112940A2 (en
Inventor
Hilde Adi Pierrette Revets
Hendricus Renerus J Hoogenboom
Els Beirnaert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ablynx NV
Original Assignee
Ablynx NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx NV filed Critical Ablynx NV
Publication of WO2007112940A2 publication Critical patent/WO2007112940A2/en
Publication of WO2007112940A3 publication Critical patent/WO2007112940A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to albumin-derived amino acid sequences that can be used to increase the half-life of therapeutic proteins and of other therapeutic compounds and entities.
PCT/EP2007/002817 2006-03-31 2007-03-29 Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same Ceased WO2007112940A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78825606P 2006-03-31 2006-03-31
US60/788,256 2006-03-31

Publications (2)

Publication Number Publication Date
WO2007112940A2 WO2007112940A2 (en) 2007-10-11
WO2007112940A3 true WO2007112940A3 (en) 2008-01-03

Family

ID=38477256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/002817 Ceased WO2007112940A2 (en) 2006-03-31 2007-03-29 Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same

Country Status (1)

Country Link
WO (1) WO2007112940A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447573B2 (en) 2016-07-20 2022-09-20 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2731617A1 (en) 2008-07-22 2010-01-28 Maria Joao Saraiva Amino acid sequences directed against multitarget scavenger receptors and polypeptides
IT1392551B1 (en) * 2008-11-25 2012-03-09 Bioindustry Park Del Canavese S P A BIOMARCERS FOR DIAGNOSIS AND TO DETECT THE PROGRESSION OF NEURODEGENERATIVE DISEASES, IN PARTICULAR OF AMIOTROPHIC LATERAL SCLEROSIS
US9493545B2 (en) 2009-02-11 2016-11-15 Albumedix A/S Albumin variants and conjugates
CA2757897A1 (en) * 2009-04-08 2010-10-14 Anna M. Wu Human protein scaffold with controlled serum pharmacokinetics
CN102741280B (en) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 Albumin variants
EP3309176B1 (en) 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
JP5969458B2 (en) 2010-04-09 2016-08-17 アルブミディクス アクティーゼルスカブ Albumin derivatives and variants
NZ603570A (en) 2010-05-20 2014-12-24 Ablynx Nv Biological materials related to her3
NZ610075A (en) 2010-11-08 2015-03-27 Novartis Ag Cxcr2 binding polypeptides
WO2012150319A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
UA117218C2 (en) 2011-05-05 2018-07-10 Мерк Патент Гмбх POLYPEPTIDE AGAINST IL-17A, IL-17F AND / OR IL17-A / F
WO2012163521A1 (en) 2011-05-27 2012-12-06 Dutalys Removal of monomeric targets
AU2012265156B2 (en) 2011-05-27 2017-01-19 F. Hoffmann-La Roche Ag Dual targeting
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
CN104736559B (en) 2012-03-16 2022-04-08 阿尔布梅迪克斯医疗有限公司 Albumin variants
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
RU2670063C2 (en) 2012-11-08 2018-10-17 Альбумедикс А/С Albumin variants
MX2018001825A (en) 2015-08-20 2018-05-07 Albumedix As Albumin variants and conjugates.
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
WO2019129221A1 (en) 2017-12-28 2019-07-04 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against tigit
KR20250114571A (en) 2018-01-15 2025-07-29 난징 레전드 바이오테크 씨오., 엘티디. Single-domain antibodies and variants thereof against pd-1
TW202003567A (en) 2018-03-30 2020-01-16 大陸商南京傳奇生物科技有限公司 Single-domain antibodies against LAG-3 and uses thereof
CN110988361B (en) * 2019-12-13 2020-09-18 山东民康生物科技有限公司 Human serum albumin removing kit
WO2024083843A1 (en) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060071A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004041863A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003060071A2 (en) * 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
WO2004041863A2 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DOCKAL M ET AL: "The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 274, no. 41, 8 October 1999 (1999-10-08), pages 29303 - 29310, XP002990741, ISSN: 0021-9258 *
FASANO M ET AL: "The extraordinary ligand binding properties of human serum albumin", IUBMB LIFE, TAYLOR AND FRANCIS, LONDON,, GB, vol. 57, no. 12, December 2005 (2005-12-01), pages 787 - 796, XP009090343, ISSN: 1521-6543 *
GIBBS W W: "NANOBODIES", SCIENTIFIC AMERICAN, SCIENTIFIC AMERICAN INC., NEW YORK, NY, US, vol. 293, no. 2, August 2005 (2005-08-01), pages 67 - 71, XP001238880, ISSN: 0036-8733 *
KRAGH-HANSEN U: "Structure and ligand binding properties of human serum albumin", DANISH MEDICAL BULLETIN, DANISH MEDICAL ASSOCIATION, COPENHAGEN, DK, vol. 37, no. 1, 1990, pages 57 - 84, XP009090324, ISSN: 0007-8916 *
REVETS H ET AL: "NANOBODIES AS NOVEL AGENTS FOR CANCER THERAPY", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, vol. 5, no. 1, 2005, pages 111 - 124, XP009076361, ISSN: 1471-2598 *
SMITH B J ET AL: "Prolonged in vivo residence times of antibody fragments associated with albumin", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US, vol. 12, no. 5, September 2001 (2001-09-01), pages 750 - 756, XP002270731, ISSN: 1043-1802 *
WANG W ET AL: "AlbuBNP, a Recombinant B-Type Natriuretic Peptide and Human Serum Albumin Fusion Hormone, as a Long-Term Therapy of Congestive Heart Failure", PHARMACEUTICAL RESEARCH, NEW YORK, NY, US, vol. 21, no. 11, November 2004 (2004-11-01), pages 2105 - 2110, XP003014318, ISSN: 0724-8741 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11447573B2 (en) 2016-07-20 2022-09-20 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof

Also Published As

Publication number Publication date
WO2007112940A2 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
WO2007112940A3 (en) Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
WO2008074840A3 (en) Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
PH12019500644A1 (en) Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
PH12013502234A1 (en) Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2009095489A3 (en) Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
MX2009002816A (en) Albumin fusion proteins.
CA2818990C (en) Designed repeat proteins binding to serum albumin
MY162737A (en) 4-1bb binding molecules
WO2011106766A3 (en) Modified proteins and methods of making and using same
UA100682C2 (en) Antibody which neutralizes human cytomegalovirus (hcmv) and use thereof
AU2008338591A8 (en) Binding molecules to the human OX40 receptor
WO2008143668A3 (en) Indoleamine-2, 3-dioxygenase-2
WO2007056681A3 (en) Methods for administering hypoglycemic agents
MY150226A (en) Novel h5 proteins, nucleic acid molecules and vectors encoding for those, and medicinal use
WO2009125409A3 (en) Fatty acid amides and uses thereof
WO2008095622A3 (en) SECRETED LUCIFERASE MLuc7 AND USE THEREOF
WO2007039903A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
WO2009035959A3 (en) Radiofluorination methods
WO2009047634A3 (en) Aqueous formulations of acetaminophen for injection
WO2009135953A3 (en) Amino acid sequences directed against integrins and uses thereof
WO2010040736A3 (en) Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
WO2010042685A3 (en) Inhibitors of the atb(0,+) transporter and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07723759

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07723759

Country of ref document: EP

Kind code of ref document: A2